68Ga-FAPI-04 PET/CT 与 18F-FDG PET/CT 在腺样囊性癌中的效用比较:两例病例报告
本文报告两例腺样囊性癌患者均接受 68Ga-FAPI-04 与 18F-FDG PET/CT 检查。第一例中 68Ga-FAPI-04 更精确地检出局部区域复发;第二例中 68Ga-FAPI-04 在病灶数量上优于 18F-FDG,并在广泛转移灶显示强烈 FAP 摄取。作者认为 68Ga-FAPI-04 PET/CT 可能有助于检出局部复发和转移,并帮助筛选适合靶向癌相关成纤维细胞的放射性核素治疗的患者。
要点
- 第一例腺样囊性癌中 68Ga-FAPI-04 PET/CT 更精确地检出局部区域复发。
- 第二例中 68Ga-FAPI-04 在病灶数量上优于 18F-FDG,广泛转移灶显示强烈 FAP 摄取。
- 作者认为 68Ga-FAPI-04 PET/CT 可能有助于检出局部复发和转移并帮助筛选放射性核素治疗患者。
核心结论
- 作者认为 68Ga-FAPI-04 PET/CT 可能有助于检出腺样囊性癌的局部复发和转移,并帮助筛选适合靶向癌相关成纤维细胞的放射性核素治疗的患者。
研究设计与样本
- 两例腺样囊性癌患者的病例报告,两例均接受 68Ga-FAPI-04 与 18F-FDG PET/CT 检查。
主要发现
- 第一例中 68Ga-FAPI-04 较 18F-FDG 更精确地检出局部区域复发。
- 第二例中 68Ga-FAPI-04 在病灶数量上优于 18F-FDG,并在广泛转移灶显示强烈 FAP 摄取。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
68 Ga-fibroblast activation protein inhibitor (FAPI) PET/CT is an emerging imaging modality with high sensitivity and high tumor-to-background ratio in various cancers including in the head and neck regions. The authors present 2 cases of adenoid cystic carcinoma who underwent 68 Ga-FAPI-04 and 18 F-FDG PET/CT. Locoregional recurrence has been detected more precisely in the first case with 68 Ga-FAPI-04. In the second case, 68 Ga-FAPI-04 outperformed 18 F-FDG in the number of lesions and demonstrated intense FAP uptake on widespread metastases, which could provide a treatment option as a theranostic concept. These cases highlight that 68 Ga-FAPI-04 PET/CT may be useful for detecting local recurrence and metastases and help select patients for radionuclide treatments targeting cancer-associated fibroblasts.
引用
- Civan C, Isik EG, Has Simsek D, et al. Utility of 68 Ga-FAPI-04 PET/CT in Adenoid Cystic Carcinoma Compared With 18 F-FDG PET/CT : Two Case Reports. Clin Nucl Med. 2023. PMID: 37167284. doi:10.1097/RLU.0000000000004687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。